What question did this study set out to answer?

To discover circulating determinants that predict pathological complete response (pCR) in patients with triple negative breast cancer undergoing neoadjuvant chemo-immunotherapy.

February 19, 2026Clinical Cancer Research

Abstract PD7-01: Circulating determinants of response to immunotherapy in triple negative breast cancer (TNBC)

Q: What does this research mean for the field?

Baseline immune profiles can predict pathological complete response (pCR) to neoadjuvant chemo-immunotherapy in triple negative breast cancer (TNBC) patients. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Authors

NSNickolas StabelliniCleveland Clinic PPP. B. ParthasarathyCleveland Clinic IGI. GautamCleveland Clinic

Discussion

Member takes

Implication

This analysis identifies immune biomarkers predicting response to immunotherapy in triple negative breast cancer, suggesting implications for patient selection.

Key Points

To discover circulating determinants that predict pathological complete response (pCR) in patients with triple negative breast cancer undergoing neoadjuvant chemo-immunotherapy.
Collected blood samples from 41 triple negative breast cancer patients at different treatment points
Utilized high-parameter flow cytometry to analyze immune cell subsets
Conducted single-cell RNA sequencing for high-throughput transcriptomic profiling
Performed plasma analysis with Olink® platform to measure cytokine levels
Employed machine learning models to identify predictors of pCR.
22 out of 41 patients achieved pCR (53.6%) while 13 had residual disease (31.7%)
pCR patients showed increased immature activated neutrophils and more B-cells at baseline
Residual disease patients had higher levels of immunosuppressive neutrophils and exhausted T-cells
Pathway analysis indicated a strong baseline interferon state in pCR patients
TRAIL and NADK were highlighted as positive predictors of pCR.

Cite This Study

Stabellini et al. (2026) studied this question.

synapsesocial.com/papers/6996a8b5ecb39a600b3efade https://doi.org/10.1158/1557-3265.sabcs25-pd7-01

View Full Paper

Ask AI

Bookmark

Implication

This analysis identifies immune biomarkers predicting response to immunotherapy in triple negative breast cancer, suggesting implications for patient selection.

Abstract PD7-01: Circulating determinants of response to immunotherapy in triple negative breast cancer (TNBC)

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PD7-01: Circulating determinants of response to immunotherapy in triple negative breast cancer (TNBC)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider